2025 Annual Work Report of the Board of Directors of Yili Chuaning Biotechnology Co., Ltd.
In 2025, the Board of Directors of Yili Chuaning Biotechnology Co., Ltd. (hereinafter referred to as "the Company") strictly adhered to the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Shenzhen Stock Exchange GEM Listing Rules, and other relevant laws, regulations, normative documents, and the Company's Articles of Association. The board diligently fulfilled the responsibilities entrusted by the shareholders' meeting. The following is the report on the work of the board for 2025:
1. Overall Business Performance in 2025
In 2025, the Company deeply studied and implemented the spirit of the 20th National Congress of the Communist Party of China, adhered to high-quality development, improved corporate governance, and effectively maintained a good image in the capital market. With the global demand for antibiotics slowing and a stable pattern in the antibiotic intermediate industry, the Company closely followed the national strategic goals for high-quality development, helping to open new avenues in the strategic emerging industry of biological manufacturing. This year, the Company fully initiated a new starting point for innovative transformation, adopting a dual-driven strategy to ensure stability in its main business while vigorously promoting its transformation into an innovative enterprise in synthetic biology. Additionally, the Company achieved certain results in product research and development, technological innovation, team building, and cost reduction and efficiency enhancement, laying a foundation for sustainable development in the future. During the reporting period, the Company achieved total operating revenue of 461,626.96 thousand yuan and a net profit attributable to shareholders of the listed company of 76,900.89 thousand yuan. As of December 31, 2025, the Company's total assets amounted to 1,042,948.03 thousand yuan, and the equity attributable to shareholders of the listed company was 808,246.68 thousand yuan.
2. Daily Work of the Board of Directors in 2025
In 2025, the Company's Board of Directors strictly complied with the Company Law, the Securities Law, the Shenzhen Stock Exchange GEM Listing Rules, and the Articles of Association, timely convening board meetings and shareholders' meetings, earnestly implementing the resolutions of the shareholders' meeting, exercising decision-making powers scientifically, and playing a core role in decision-making, ensuring the Company's standardized and efficient operation.
(1) Board Meeting Attendance
In 2025, the Company held a total of 5 board meetings, with the convening procedures for each meeting complying with the relevant provisions of the Company Law and the Articles of Association. The specific work of the board is as follows: